Similar articles

• Looking at US versus European exit opportunities.

  Lawrence S. Lawrence S. Nat Biotechnol. 2005 Oct;23(10):1203. Nat Biotechnol. 2005. PMID: 16302294 No abstract available.
• Mind the (biomedical funding) gap.

  Klausner A. Klausner A. Nat Biotechnol. 2005 Oct;23(10):1217-8. doi: 10.1038/nbt1005-1217. Nat Biotechnol. 2005. PMID: 16211055 No abstract available.
• The rise of European venture capital for biotechnology.

  Howell M, Trull M, Dibner MD. Howell M, et al. Nat Biotechnol. 2003 Nov;21(11):1287-91. doi: 10.1038/nbt1103-1287. Nat Biotechnol. 2003. PMID: 14595356 No abstract available.
• Hurdles and opportunities for a venture capitalist investing in therapies for orphan retinal diseases.

  Blair JC. Blair JC. Retina. 2005 Dec;25(8 Suppl):S105-S108. doi: 10.1097/00006982-200512001-00054. Retina. 2005. PMID: 16374312 Review. No abstract available.
• Medical entrepreneurism: the current opportunity in America.

  Lexa FJ. Lexa FJ. J Am Coll Radiol. 2004 Oct;1(10):762-8. doi: 10.1016/j.jacr.2004.05.011. J Am Coll Radiol. 2004. PMID: 17411697 Review.